Directly from the dpa news channel
Mainz (dpa / lrs) – Mainz researchers will receive € 13 million from the German Research Foundation to continue their search for the smallest active ingredients in oncology. The University of Mainz announced Friday that the goal of the Collaborative Research Center is to be able to permanently eliminate even the minimum remaining diseases, such as undetected and undiagnosed metastases. It participates in the Center for Collaborative Research with other departments of the University of Johannes Gutenberg and the Max Planck Institute for Polymer Research in Mainz.
The renewed funding underscores Mainz’s importance as a science site in biotechnology, immunology, and polymer research, as explained by University Medicine.
The research was funded for eight years. The renewable financing period is four years. The pioneering work of founders Biontech Ugur Sahin and Özlem Türeci shows that the clinical application of these small nanoparticle carriers can lead to “excellent results” and that nucleic acid-based immunotherapy treatments can be developed. Both worked for years as scientists at the University Medical Center in Mainz.
© dpa-infocom, dpa: 210528-99-778864 / 3